The company cut back in areas while investing in internal and external opportunities to offset the loss of exclusivity on a ...

Seven Novo Nordisk board members have resigned. The new board headed by former Novo Nordisk CEO Lars Rebien Sørensen will ...

The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress ...

Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell ...

The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation ...

With data from the Phase III STELLAR-303 study in third-line metastatic colorectal cancer in the books, Exelixis is plotting ...

In May, Summit released early data from the Phase III HARMONi study showing that while the PD-1/VEGF inhibitor resulted in ...

The death occurred in a patient who had a complex medical background and who was being managed with several drugs, according ...

In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how ...

Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...

AI is changing the nature of leadership in biopharma. Here’s how executives can not only adapt, but lead the way.

Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework ...